Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings in Brief: ResMed

This article was originally published in The Gray Sheet

Executive Summary

ResMed: Obstructive sleep apnea (OSA) treatment products firm expects to net about $24-$25 mil. from initial public offering, assuming the exercise of overallotments by underwriters Robertson Stephens & Co., William Blair & Co. and Nonumura Securities. The Australia-based firm's stock began trading June 2 on NASDAQ in conjunction with an offering of 3 mil. shares at $11 per share. Of the shares, 2 mil. were sold by the company, and 1 mil. were offered by selling shareholders. The company plans to use the bulk of the proceeds for working capital. In addition, about $1 mil. is earmarked for expanding manufacturing, and another "portion" may be used to expand sales, marketing and distribution capabilities. ResMed, known before the offering and outside the U.S. as ResCare, offers a number of air flow generators and accessories for the treatment of OSA. For the six months ended Dec. 31, the company reported net income of $1.1 mil. on $10.4 mil. in revenues.

You may also be interested in...



Real World Data Failed To Impress Kaftrio’s European Reviewers

The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.

Swissmedic Clears Up Confusion Over Validity Of GMP Certificates

Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.

People On The Move: Appointments At Stada, PGEU, And UK Health Claims Committee

Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.

UsernamePublicRestriction

Register

OM011382

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel